COVID-19 Virus Detection
Microfluidics Technology in Infectious Disease Research and Surveillance
In a short period of time, a novel coronavirus (SARS-CoV-2) has impacted our lives, society and health care infrastructure. To address critical needs for clinical research and public health surveillance, Standard BioTools™ products are supporting global laboratory efforts by delivering
- cost-efficient workflows that minimize reagent consumption using microfluidics technology
- scalable throughput that enables the testing of >6,000 samples per day
- flexible panel designs that enable users to easily add, remove or change assays without changing technologies.
Labs around the world have leveraged the benefits of Standard BioTools microfluidics for research and implemented high-throughput lab developed tests (LDT) for SARS-CoV-2 detection.
Whether you are seeking to gain new insights into infectious disease research or public health surveillance or to accelerate therapeutic development, we can help you reach your goal.
The authors describe the use of Biomark™ HD in a study focusing on severe COVID-19 infections. The study found decreased T cell populations along with down-regulated gene expression related to T cell activation and differentiation, “which may help to provide effective treatment strategies for COVID-19.”
Review the latest press releases about viral detection and infectious disease research by Standard BioTools and our customers and partners below:
Available now: Pathogen Detection using the Advanta RT-PCR Kit
Infectious disease research and surveillance play a critical role in improving global health care. Information acquired from research drives public health policy for preventive measures, drug treatment and vaccine development. PCR-based applications such as reverse transcription PCR (RT-PCR) are commonly used to detect viral and bacterial pathogens.
The Advanta RT-PCR Kit—192.24 provides scalable, high-throughput pathogen detection through nanoliter-scale volumes with walkaway automation. Using the 192.24 Dynamic Array™ IFC (integrated fluidic circuit) enables rapid data acquisition of up to 192 samples across 24 targets: up to 4,608 reactions every 35 minutes.
For Research Use Only. Not for use in diagnostic procedures.
Advanta RT-PCR Kit—192.24, 10 IFCs
This kit enables probe-based quantitative PCR of 1,920 samples and combines reverse transcription and preamplification in a single step.
|Proprietary microfluidics technology||Nanoliter-volume reactions ensure low cost per sample.|
|Modular system that allows up to 6,000 samples to be processed in a day||Highly scalable to fit laboratory’s needs|
|Up to 24 molecular targets in a single run||Preserve precious sample while providing comprehensive molecular pictures of the sample.|
|Up to 4,608 datapoints in a single run||Save time by accessing more information per run.|
With the Biomark HD system, you get reliable production-scale throughput and excellent sensitivity, with a wide variety of sample types and chemistry choices to accommodate the most genomic applications.
Scalable, High-Throughput Viral RNA Detection
Efficient—Maximize your budget with microfluidics technology by using up to 50 times less reagent than traditional PCR methods.
Scalable—Run nearly 6,000 samples in a 24-hour workflow on each Biomark HD and Juno™ system.
Flexible—Detect up to 24 unique pathogens per sample, such as SARS-CoV-2, influenza A and other respiratory disease pathogens.